Results 81 to 90 of about 1,927 (159)

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection [PDF]

, 2008
David A. Cooper, Roy T. Steigbigel, José M. Gatell, Jürgen K. Rockstroh, Christine Katlama, Patrick Yéni, Adriano Lazzarin, Bonaventura Clotet, Princy Kumar, Joseph Eron, Mauro Schechter, Martin Markowitz, Mona Loutfy, Jeffrey L. Lennox, Jing Zhao, Joshua Chen, Desmon̄d Ryan, Rand R. Rhodes, John A. Killar, Lucinda R. Gilde, Kim M. Strohmaier, Anne R. Meibohm, Michael D. Miller, Daria J. Hazuda, Michael L. Nessly, Mark J. DiNubile, Robin Isaacs, Hedy Teppler, Bach-Yen Nguyen   +28 more
openalex   +1 more source

Long-term efficacy and safety of raltegravir in the management of HIV infection

Infection and Drug Resistance, 2014
Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC   +4 more
doaj  

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

Adolescent Health, Medicine and Therapeutics, 2013
Kajal B Larson, Jennifer R King, Edward P Acosta Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA Abstract: Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA,
Larson KB, King JR, Acosta EP
doaj  

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants [PDF]

, 2008
Jessica Marinello, Christophe Marchand, Bryan T. Mott, Anjali Bain, Craig J. Thomas, Yves Pommier   +5 more
openalex   +1 more source

Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts) [PDF]

, 2008
Francesca Gatti, A. Matti, Paola Nasta, Giuliana Cologni, Silvia Costarelli, Giampiero Carosi   +5 more
openalex   +1 more source

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection

Терапевтический архив, 2014
AIM. To evaluate the efficiency and safety of using raltegravir (RAL) twice daily in conjunction with a once-daily fixed dose combination of abacavir (ABC)/lamivudine (3TC) in patients with HIV infection and active tuberculosis who have not previously ...
A V Kravchenko, V N Zimina, A A Popova, M O Deulina, V G Kanestri, É S Ivanova, A A Iakovlev, V V Pokrovskiĭ   +7 more
doaj  

No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo [PDF]

, 2008
Homayoon Khanlou, Shilpa Sayana, Edward P. Acosta   +2 more
openalex   +1 more source

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir [PDF]

, 2009
William D. Hanley, Larissa Wenning, Allison R. Moreau, James Kost, Eric Mangin, Trisha Shamp, Julie A. Stone, Keith Gottesdiener, John A. Wagner, Marian Iwamoto   +9 more
openalex   +1 more source

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors [PDF]

, 2009
Erik Serrao, Srinivas Odde, Kavya Ramkumar, Nouri Neamati   +3 more
openalex   +1 more source